Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release Galera Therapeutics Announces Dosing Of First Patient In A Randomized Double Blind Pilot Phase 2 Clinical Trial Of Gc4419 For Covid 19 is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.Search RobinsPost News & Noticias
Galera Therapeutics Announces Dosing of First Patient in a Randomized ...

The randomized, double-blind, placebo-controlled Phase 2 trial is designed to assess the safety and efficacy of GC4419 in improving 28-day mortality, compared to placebo. The trial will enroll up ... Read More
Galera Therapeutics Announces Dosing of First Patient in the Phase 1/2 ...

Trial Supported in Part by NIH SBIR GrantMALVERN, Pa., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing ... Read More
Seneca Therapeutics Announces the Dosing of the First Patient in the ...

The Phase I/II trial will assess the safety and preliminary efficacy of Seneca Valley Virus (SVV-001) in combination with the checkpoint inhibitors nivolumab and ipilimumab in the treatment of ... Read More
Virios Therapeutics’ Announces Dosing of First Patient in IMC-2 Long ...

Virios Therapeutics’ Announces Dosing of First Patient in IMC-2 Long-COVID Treatment Trial -New Long-COVID Research Program Complements Fibromyalgia Phase 2b Clinical Research Program- ... Read More
First Patient Randomized in Jaguar Health's Phase 2 Randomized, Double ...

“The results of Napo’s randomized double-blind, placebo-controlled Phase 2 study of crofelemer in pediatric MVID patients are expected to be available in the second half of 2026. Read More
Spyre Therapeutics Announces Positive Interim Phase 1 Results ... - KTLA

The SPY002 and SPY072 Phase 1 trials are first-in-human, randomized, double-blind, placebo-controlled trials designed to evaluate safety, PK, and PD in healthy volunteers. Read More
BioCardia Announces First Patient in Phase 3 Randomized Controlled ...

A Double-blind, Randomized Controlled Trial of an Autologous Cell Therapy in Patients with HFrEF: Principal Results from the CardiAMP-HF Trial, American College of Cardiology Scientific Sessions ... Read More
Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a ...

The initiation of this Phase 1 trial represents an important step in the clinical evaluation of ATR as a target for cancer therapy." About Aprea Therapeutics, Inc. Read More
Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial ...

Phase 1 clinical trial dosing of first patient complete; primary objective to assess safety/tolerability and absolute bioavailability of TH104 Company fully funded into 2025 with full readouts of ... Read More
Galera Therapeutics Announces Dosing of First Patient in a Randomized ...

The randomized, double-blind, placebo-controlled Phase 2 trial is designed to assess the safety and efficacy of GC4419 in improving 28-day mortality, compared to placebo. The trial will enroll up ... Read More
DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 ...

“We are extremely excited to announce the dosing of the first patient in the PE trial,” said Rick Pauls, President and Chief Executive Officer of DiaMedica Therapeutics. Read More
Blow Us A Whistle

Comments (Whistles) Designed By Disqus